FDA Accepts Supplement Application for RoxyBond (NDA209777)
The FDA has accepted a supplemental application for RoxyBond, an oxycodone hydrochloride formulation.
Company
Pharmaceutical intelligence for Protega Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.